ARTICLE | Clinical News
NPSP795: Phase IIa started
August 11, 2014 7:00 AM UTC
NPS began an open-label, dose-escalation, U.S. Phase IIa trial to evaluate IV NPSP795 in up to 12 patients with ADH, a genetic disorder of calcium homeostasis. NPSP795 was discovered using NPS’s calci...